Despite the existence of effective interventions for anxiety disorders, relapse – or the return of fear – presents a significant problem for patients and clinicians in the longer term. The present paper draws on the experimental and clinical behavioural literature, reviewing the mechanisms by which the return of fear can occur. The aim of the paper was to generate a list of treatment recommendations for clinicians aimed at reducing relapse in successfully treated anxiety disorders. Clinical and experimental literature on the mechanisms of renewal, reinstatement, spontaneous recovery and reacquisition are reviewed. These are linked with the clinical and experimental literature on the return of fear in successfully treated anxiety. A list of recommendations to assist in reducing the probability of relapse in successfully treated anxiety is presented. This list includes methods for use in behavioural (exposure) treatment of anxiety disorders that aim to enhance clinical outcomes. Despite the significant problem of relapse in successfully treated anxiety, there are methods available to reduce the probability of relapse through return of fear. Clinicians engaging in treatment of anxiety disorders should be mindful of these methods to ensure optimal patient outcome.
1 September 2007 in Behaviour Research and Therapy
Background This study examined the feasibility and preliminary effectiveness of d‐cycloserine (DCS)–augmented cognitive behavioral therapy (CBT) for children and adolescents with difficult‐to‐treat Obsessive Compulsive Disorder, in a double‐blind randomized controlled pilot trial (RCT). Methods Seventeen children and adolescents (aged 8–18 years) with a primary diagnosis of OCD, which was deemed difficult‐to‐treat, were randomly assigned to either nine sessions of CBT including five sessions of DCS‐augmented exposure and response prevention (ERP) [ERP + DCS] or nine sessions of CBT including five sessions of placebo‐augmented ERP [ERP + PBO]. Weight‐dependent DCS or placebo doses (25 or 50 mg) were taken 1 hour before ERP sessions. Results At posttreatment, both groups showed significant improvements with 94% of the entire sample classified as responders. However, a greater improvement in the ERP + DCS relative to the ERP + PBO condition was observed at 1‐month follow‐up on clinician‐rated obsessional severity and diagnostic severity, and parent ratings of OCD severity. There were no changes across time or condition from 1‐ to 3‐month follow‐up. Conclusions In this preliminary study, DCS‐augmented ERP produced significant improvements in OCD severity from posttreatment to 1‐month follow‐up, relative to a placebo control condition, in severe and difficult‐to‐treat pediatric OCD. The significant effect on obsessional severity suggests that DCS augmentation might be associated with enhanced modification of obsessional thoughts during ERP, and warrants further investigation.